Semaglutide Versus Dulaglutide and Liraglutide in Chinese Patients With T2DM : A Multicenter Real‐World Study
Authors' conclusion
Semaglutide demonstrated superior glycemic control and weight loss compared to both dulaglutide and liraglutide, whereas dulaglutide and liraglutide exhibited comparable clinical efficacy.
Study context
- Population
- Chinese adults with T2DM initiating GLP-1 RA therapy in endocrinology clinics, January 1, 2022–August 31, 2024
- Participants
- 111 / 74 / 107
- Exposure
- Semaglutide 1.0 mg vs dulaglutide 1.5 mg vs liraglutide 1.8 mg
- Semaglutiden = 111
- Dulaglutiden = 74reference
- Liraglutiden = 107reference
- Outcome
- HbA1c reduction
Methodological detailsmulticenter, real-world, 1:1 propensity score matching
- Multicenter
- Real-world
- 1:1 propensity score matching
Main finding
As reported in the abstract
Difference
−0.27 %
P = 0.008
Semaglutide vs Dulaglutide · ± 0.70%; greater reduction with semaglutide
Difference
−0.39 %
P < 0.001
Semaglutide vs Liraglutide · ± 0.87%; greater reduction with semaglutide
Observational data: associations, not effects.
Further findings
Glycemic target achievement
- Higher glycemic target achievement rates with semaglutide vs dulaglutide and liraglutide
Projected long-term outcomes (UKPDS Outcomes Model 2.1)
- Semaglutide associated with improved outcomes in all death, CV death and other death endpoints
Safety
Safety (key exploratory endpoint)
- No significant differences in safety profiles among the three groups
Original publication
Semaglutide Versus Dulaglutide and Liraglutide in Chinese Patients With T2DM : A Multicenter Real‐World Study. Obesity (Silver Spring). Published 20 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →